Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biodesix, Inc. - Common Stock (NQ: BDSX )

1.030 +0.130 (+14.44%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Biodesix, Inc. - Common Stock

< Previous 1 2 3 4 Next >
Biodesix Announces Second Quarter 2023 Results and Highlights
From Biodesix, Inc.
Via Business Wire
Biodesix to Participate in the Canaccord Genuity 43rd Annual Growth Conference
From Biodesix, Inc.
Via Business Wire
Biodesix to Report Second Quarter 2023 Financial Results on August 7, 2023
From Biodesix, Inc.
Via Business Wire
Biodesix Announces Publication of the ORACLE Clinical Utility Study with the Primary Endpoint Demonstrating that the Nodify XL2® Test Reduced Unnecessary Invasive Procedures on Benign Lung Nodules
From Biodesix, Inc.
Via Business Wire
Biodesix Awarded Advanced Diagnostic Laboratory Test Status for its Nodify CDT® Test by the Center for Medicare and Medicaid Services
From Biodesix, Inc.
Via Business Wire
Biodesix Completes Enrollment of INSIGHT Study Assessing Clinical Utility of the VeriStrat® Blood-Based Host Immune Classifier
From Biodesix, Inc.
Via Business Wire
Biodesix Announces Three Abstracts to Be Presented at ASCO 2023 Annual Meeting
From Biodesix, Inc.
Via Business Wire
Biodesix to Participate in William Blair’s 43rd Annual Growth Stock Conference
From Biodesix, Inc.
Via Business Wire
Biodesix Announces Four Presentations of Health Economic Data Highlighting Cost Saving Potential of Nodify Lung® Testing
From Biodesix, Inc.
Via Business Wire
Biodesix, Inc. Chief Financial Officer Robin Harper Cowie Appointed to Colorado BioScience Association's Board of Directors
From Biodesix, Inc.
Via Business Wire
Biodesix Announces New Clinical Utility Evidence for the Nodify XL2® Nodule Risk Assessment Test to Be Presented at ATS 2023 International Conference
From Biodesix, Inc.
Via Business Wire
Biodesix Announces First Quarter 2023 Results and Highlights
From Biodesix, Inc.
Via Business Wire
Biodesix to Report First Quarter 2023 Financial Results on May 11, 2023
From Biodesix, Inc.
Via Business Wire
Biodesix Announces Fourth Quarter and Fiscal Year End 2022 Results and Highlights
From Biodesix, Inc.
Via Business Wire
Biodesix to Participate at Cowen’s 43rd Annual Healthcare Conference
From Biodesix, Inc.
Via Business Wire
Biodesix to Report Fourth Quarter and Full Year 2022 Financial Results on March 6, 2023
From Biodesix, Inc.
Via Business Wire
Biodesix Announces First Four Private Payer Coverage Policies for the Nodify XL2® Test
From Biodesix, Inc.
Via Business Wire
Biodesix Announces Appointment of Lawrence (Lair) T. Kennedy, Jr. to Board of Directors
From Biodesix, Inc.
Via Business Wire
Biodesix Ranked Top Proteomics Solutions Company by Life Sciences Review Magazine
From Biodesix, Inc.
Via Business Wire
Biodesix Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional Shares
From Biodesix, Inc.
Via Business Wire
Biodesix Announces Pricing of $35.1 Million Upsized Public Offering of Common Stock
From Biodesix, Inc.
Via Business Wire
Biodesix Announces Proposed Public Offering of Common Stock
From Biodesix, Inc.
Via Business Wire
Biodesix Announces Senior Secured Financing Agreement with Perceptive Advisors for Up to $50 Million
From Biodesix, Inc.
Via Business Wire
Biodesix Presents New Data from the INSIGHT Study at the 2022 Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
From Biodesix, Inc.
Via Business Wire
Biodesix Announces Third Quarter 2022 Results and Highlights
From Biodesix, Inc.
Via Business Wire
Biodesix to Report Third Quarter 2022 Financial Results on November 3, 2022
From Biodesix, Inc.
Via Business Wire
Biodesix Awarded U.S. Federal Supply Schedule Contract for Its Comprehensive Lung Cancer Diagnostic Testing Solutions
From Biodesix, Inc.
Via Business Wire
Biodesix to Present Data at the CHEST 2022 Annual Meeting Demonstrating High Sensitivity of the Nodify XL2® Blood-Based Lung Nodule Test in Various Patient Populations, Including Individuals Participating in Lung Cancer Screening Programs
From Biodesix, Inc.
Via Business Wire
Biodesix Announces Preliminary Revenue for Third Quarter 2022
From Biodesix, Inc.
Via Business Wire
Biodesix to Participate in Two Upcoming Investor Conferences in September
From Biodesix, Inc.
Via Business Wire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.